口服司美格鲁肽与2型糖尿病患者的心血管结局
PIONEER 6是一项事件驱动、随机、双盲、安慰剂对照试验,纳入3183例高心血管风险的2型糖尿病患者(≥50岁合并确诊心血管或慢性肾脏病,或≥60岁仅有心血管危险因素),随机接受每日一次口服司美格鲁肽或安慰剂。主要终点为主要不良心血管事件(心血管死亡、非致死性心肌梗死或非致死性卒中)首次发生,预设非劣效界值为HR 95%CI上限1.8。中位随访15.9个月,主要终点事件口服司美格鲁肽组61/1591例(3.8%) vs 安慰剂组76/1592例(4.8%),HR 0.79(95%CI 0.57-1.11),非劣效P<0.001。结论为口服司美格鲁肽的心血管风险不劣于安慰剂。
要点
- 高心血管风险2型糖尿病患者中,口服司美格鲁肽主要不良心血管事件3.8%(61/1591) vs 安慰剂4.8%(76/1592),HR 0.79(95%CI 0.57-1.11),非劣效P<0.001。
- 心血管死亡:口服司美格鲁肽组0.9%(15/1591) vs 安慰剂组1.9%(30/1592),HR 0.49(95%CI 0.27-0.92)。
- 全因死亡:口服司美格鲁肽组1.4%(23/1591) vs 安慰剂组2.8%(45/1592),HR 0.51(95%CI 0.31-0.84)。
- 非致死性心肌梗死:口服司美格鲁肽组2.3%(37/1591) vs 安慰剂组1.9%(31/1592),HR 1.18(95%CI 0.73-1.90);非致死性卒中:0.8%(12/1591) vs 1.0%(16/1592),HR 0.74(95%CI 0.35-1.57)。
- 导致停用口服司美格鲁肽或安慰剂的胃肠道不良事件在口服司美格鲁肽组更常见。
适用人群与场景
- 年龄≥50岁且已确诊心血管疾病或慢性肾脏病,或年龄≥60岁且仅有心血管危险因素的2型糖尿病高心血管风险患者。
研究设计与关键结果
- 事件驱动、随机、双盲、安慰剂对照试验,共纳入3183例患者,随机接受每日一次口服司美格鲁肽或安慰剂。
- 患者平均年龄66岁;2695例(84.7%)为≥50岁且合并心血管或慢性肾脏病。
- 中位试验时间15.9个月。
- 主要终点(心血管死亡、非致死性心肌梗死或非致死性卒中首次发生):口服司美格鲁肽组61/1591例(3.8%) vs 安慰剂组76/1592例(4.8%),HR 0.79(95%CI 0.57-1.11),非劣效P<0.001,非劣效界值为HR 95%CI上限1.8。
- 心血管死亡:口服司美格鲁肽组15/1591例(0.9%) vs 安慰剂组30/1592例(1.9%),HR 0.49(95%CI 0.27-0.92)。
- 非致死性心肌梗死:口服司美格鲁肽组37/1591例(2.3%) vs 安慰剂组31/1592例(1.9%),HR 1.18(95%CI 0.73-1.90)。
- 非致死性卒中:口服司美格鲁肽组12/1591例(0.8%) vs 安慰剂组16/1592例(1.0%),HR 0.74(95%CI 0.35-1.57)。
- 全因死亡:口服司美格鲁肽组23/1591例(1.4%) vs 安慰剂组45/1592例(2.8%),HR 0.51(95%CI 0.31-0.84);导致停用口服司美格鲁肽或安慰剂的胃肠道不良事件在口服司美格鲁肽组更常见。
证据类型、等级与局限
- 证据类型:随机、双盲、安慰剂对照试验(PIONEER 6)。
- 结论:在2型糖尿病患者中,口服司美格鲁肽的心血管风险不劣于安慰剂。
- 局限:原文未报告局限性。
对床旁实践的改变
- 对于高心血管风险的2型糖尿病患者,口服司美格鲁肽的心血管风险不劣于安慰剂,主要不良心血管事件HR 0.79(95%CI 0.57-1.11)。
- 口服司美格鲁肽组全因死亡HR 0.51(95%CI 0.31-0.84)及心血管死亡HR 0.49(95%CI 0.27-0.92)较安慰剂组低。
- 导致停药的胃肠道不良事件在口服司美格鲁肽组更常见。
指南或共识出处
- PIONEER 6(ClinicalTrials.gov number, NCT02692716),由Novo Nordisk资助。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Establishing cardiovascular safety of new therapies for type 2 diabetes is important. Safety data are available for the subcutaneous form of the glucagon-like peptide-1 receptor agonist semaglutide but are needed for oral semaglutide.
METHODS: We assessed cardiovascular outcomes of once-daily oral semaglutide in an event-driven, randomized, double-blind, placebo-controlled trial involving patients at high cardiovascular risk (age of ≥50 years with established cardiovascular or chronic kidney disease, or age of ≥60 years with cardiovascular risk factors only). The primary outcome in a time-to-event analysis was the first occurrence of a major adverse cardiovascular event (death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke). The trial was designed to rule out 80% excess cardiovascular risk as compared with placebo (noninferiority margin of 1.8 for the upper boundary of the 95% confidence interval for the hazard ratio for the primary outcome).
RESULTS: A total of 3183 patients were randomly assigned to receive oral semaglutide or placebo. The mean age of the patients was 66 years; 2695 patients (84.7%) were 50 years of age or older and had cardiovascular or chronic kidney disease. The median time in the trial was 15.9 months. Major adverse cardiovascular events occurred in 61 of 1591 patients (3.8%) in the oral semaglutide group and 76 of 1592 (4.8%) in the placebo group (hazard ratio, 0.79; 95% confidence interval [CI], 0.57 to 1.11; P<0.001 for noninferiority). Results for components of the primary outcome were as follows: death from cardiovascular causes, 15 of 1591 patients (0.9%) in the oral semaglutide group and 30 of 1592 (1.9%) in the placebo group (hazard ratio, 0.49; 95% CI, 0.27 to 0.92); nonfatal myocardial infarction, 37 of 1591 patients (2.3%) and 31 of 1592 (1.9%), respectively (hazard ratio, 1.18; 95% CI, 0.73 to 1.90); and nonfatal stroke, 12 of 1591 patients (0.8%) and 16 of 1592 (1.0%), respectively (hazard ratio, 0.74; 95% CI, 0.35 to 1.57). Death from any cause occurred in 23 of 1591 patients (1.4%) in the oral semaglutide group and 45 of 1592 (2.8%) in the placebo group (hazard ratio, 0.51; 95% CI, 0.31 to 0.84). Gastrointestinal adverse events leading to discontinuation of oral semaglutide or placebo were more common with oral semaglutide.
CONCLUSIONS: In this trial involving patients with type 2 diabetes, the cardiovascular risk profile of oral semaglutide was not inferior to that of placebo. (Funded by Novo Nordisk; PIONEER 6 ClinicalTrials.gov number, NCT02692716.).
参考来源
- Husain M, Birkenfeld AL, Donsmark M, et al. Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med. 2019. PMID: 31185157. doi:10.1056/NEJMoa1901118
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。